MedPath

Efficacy and safety of CH-001 in patients with chronic hepatitis C or NAFLD/NASH (placebo comparative study)

Not Applicable
Recruiting
Conditions
Chronic hepatitis C or NAFLD/NASH
Registration Number
JPRN-UMIN000006928
Lead Sponsor
Kyoundo Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

[All subjects] 1) Decompensated cirrhosis 2) Other hepatitis virus infections 3) HIV positive 4) Serious chronic bacterial infections 5) Malignant tumour 6) Autoimmune hepatic disorders 7) Alcoholic hepatic disorders or daily alcoholic intake of more than 20g/day 8) Drug-induced hepatic disorders 9) Fulminant hepatitis 10) Biliary disorders 11) Cardiac, renal, or spleen complications requiring hospitalized therapy 12) Sensory disorders due to severe peripheral circulatory disorders 13) During pregnancy/breast feeding, presenting signs of pregnancy, or planning to be pregnant 14) Anti-oxidative therapy within 4 weeks before screening 15) Implantable medical electronics (MEs), life-sustaining MEs, or body-worn MEs [HepC] 1) Interferon and/or ribavirin therapy within 26 weeks before screening 2) Therapy with choleretics, glycyrrhizin compounds, or others within 4 weeks before screening [NAFLD/NASH] 1) Start of therapy with insulin sensitizers, lipid lowering drugs, or others within 4 weeks before screening 2) Start of dietary and/or exercise therapy within 4 weeks before screening 3) Surgical treatments for severe obesity within 4 weeks before screening

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ALT after 8-week treatment
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath